SIM
MTNB icon

Spark Investment Management’s Matinas BioPharma MTNB Stock Holding History

Spark Investment Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-760
Closed -$105K – 829
2017
Q1 		$105K Buy
+760
New +$124K 0.01% 773

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Spark Investment Management's MTNB Position: Q2 2017 in Review

Spark Investment Management sold out of Matinas BioPharma (MTNB) in Q2 2017, closing a stake of 760 shares — an estimated $105K sold.

Spark Investment Management first reported a position in MTNB in Q1 2017 and held it in 1 quarter. The position peaked at $105K in Q1 2017. 45 funds tracked by Wall St. Rank hold MTNB as of Q2 2017.

  • Spark Investment Management reported no remaining Matinas BioPharma position as of Q2 2017 after selling out during the quarter.
  • Spark Investment Management sold 760 Matinas BioPharma shares in Q2 2017, an estimated $105K.
  • Spark Investment Management first reported a position in Matinas BioPharma in Q1 2017 and held it in 1 quarter.
  • Spark Investment Management's Matinas BioPharma position peaked at $105K in Q1 2017.
  • 45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2017.

Based on Spark Investment Management's 13F filing for Q2 2017, filed 27 Jul 2017.